Related Experiment Videos
Apolipoprotein E polymorphism and coronary artery disease
Insights
Apolipoprotein E3/2 heterozygosity may protect against atherosclerosis, while E2/2 homozygosity doesn't increase coronary risk. This study analyzed lipid status and apolipoprotein E phenotypes in patients and controls.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Biochemistry
Background:
- Apolipoprotein E (ApoE) phenotypes influence lipid metabolism and cardiovascular disease risk.
- Understanding the association between ApoE phenotypes and coronary atherosclerosis is crucial for risk stratification.
Purpose of the Study:
- To investigate the relationship between lipid profiles, apolipoprotein E phenotypes, and coronary atherosclerosis in a patient cohort.
- To determine the specific roles of different ApoE genotypes in the development of coronary artery disease.
Main Methods:
- Lipid status and apolipoprotein E phenotypes were analyzed in 1000 patients undergoing coronary angiography and 1000 healthy factory employees.
- Frequencies of six distinct apolipoprotein E phenotypes (E3/3, E4/4, E2/2, E4/3, E3/2, E4/2) were determined in both groups.
- Biochemical markers including cholesterol, triglycerides, and high-density lipoprotein cholesterol were measured.
Main Results:
- Apolipoprotein E3/2 heterozygotes were found more frequently in patients without coronary sclerosis, suggesting a protective effect.
- Cholesterol and triglyceride levels were significantly elevated in patients with coronary artery disease.
- Apolipoprotein E2/2 homozygosity was not associated with an increased risk of coronary atherosclerosis, despite elevated beta-very low-density lipoproteins.
Conclusions:
- Apolipoprotein E3/2 heterozygosity may confer a protective effect against early atherosclerosis.
- Apolipoprotein E2/2 homozygosity is not a reliable biochemical indicator for increased coronary atherosclerosis risk.
- Lipid profiles, particularly elevated cholesterol and triglycerides, are significant indicators of coronary artery disease.
Abstract:
Lipid status and apolipoprotein E phenotypes were tested in 1000 patients who underwent coronary angiography. The same number of factory employees was chosen as a control group. We distinguished between six different apolipoprotein E phenotypes and determined their frequencies in all groups. For the three homozygous phenotypes E3/3, E4/4, and E2/2, the percentage distribution in the group of factory employees was 62.7%, 2.3%, and 0.8%, respectively; for the three heterozygous phenotypes E4/3, E3/2, and E4/2, we determined frequencies of 20.3%, 11.0%, and 3.0%, respectively. In the group of patients with and without signs of coronary atherosclerosis, we observed almost the same frequencies except that heterozygotes (E3/2) occurred significantly more frequently in the group of coronary angiography patients unaffected by coronary sclerosis. Cholesterol and triglyceride values were significantly elevated in patients with coronary artery disease, whereas high density lipoprotein cholesterol levels were not significantly different. The data further suggest that apolipoprotein E2/2 homozygosity, despite the presence of beta-very low density lipoproteins in the plasma of these patients, cannot be considered a biochemical indicator of an increased risk of coronary atherosclerosis. On the other hand, apolipoprotein E3/2 heterozygosity may have a protective effect on the development of early atherosclerosis.